MALE MEDICAL FERTILITY TREATMENT: HCG + PHARMACEUTICAL URINARY LH + FSH
TO INCREASE SPERM COUNT THROUGH SPERMATOGENESIS
National Medical Clinic, Inc. physicians provide a Male Medical Fertility Treatment consisting of the administration of Human Chorionic Gonadotropin (HCG), Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) to increase male fertility (sperm count) or spermatogenesis in hypogonadotropic men when the pituitary gland is not secreting sufficient FSH, or is deficient in the production of both LH and FSH, such that spermatogenesis does not occur.
The purpose of HCG treatment with regard to male infertility is to increase spermatogenesis in hypogonadotropic men deficient in FSH, or is deficient in the production of both LH and FSH. The use of pharmaceutically manufactured gonadotropin LH combines with HCG to replace insufficient LH secretion by the pituitary. FSH is available mixed with LH in the form of Pergonal® or Menopur®, and other more purified forms of gonadotropins, as well as in a pure forms as recombinant FSH (Gonal F, Follistim). This treatment combines pharmacy compounded or manufactured HCG with pharmaceutically manufactured gonadotropin LH and FSH to induce spermatogenesis in hypogonadotropic men when the pituitary gland is not secreting sufficient LH, FSH or is deficient in the production of both LH and FSH such that spermatogenesis does not occur.
Hypogonadism is a medical term for a defect of the reproductive system that results in lack of function of the gonads (ovaries or testes). The gonads have two functions: to produce hormones (testosterone, estradiol, antimullerian hormone, progesterone, inhibin B), activin and to produce gametes (eggs or sperm). Deficiency of sex hormones can result in defective primary or secondary sexual development, or withdrawal effects (e.g., premature menopause) in adults. Defective egg or sperm development results in infertility.
Follicle-stimulating hormone (FSH) is a hormone synthesized and secreted by gonad tropes in the anterior pituitary gland. FSH regulates the development, growth, pubertal maturation, and reproductive processes of the human body. FSH and Luteinizing hormone (LH) act synergistically in reproduction. In males, FSH enhances the production of androgen-binding protein by the Sertoli cells of the testes, and is critical for spermatogenesis.
In males, FSH enhances the production of androgen-binding protein by the Sertoli cells of the testes, and is critical for spermatogenesis. FSH regulates the reproductive processes of the human body. Both LH (or HCG as a medication substitute for naturally produced LH) and FSH must be present for spermatogenesis. (Source: Wikipedia).
Luteinizing hormone (LH) is a hormone produced by the anterior pituitary gland. LH is a glycoprotein. Each monomeric unit is a sugar-like protein molecule; two of these make the full, functional protein. Its structure is similar to the other glycoproteins, follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), and human chorionic gonadotropin (hCG). The protein dimer contains 2 polypeptide units, labeled alpha and beta subunits that are connected by two disulfide bridges:
In both males and females, LH is essential for reproduction. In the male, LH acts upon the Leydig cells of the testis and is responsible for the production of testosterone, an androgen that exerts both endocrine activity and intratesticular activity such as spermatogenesis.
The release of LH at the pituitary gland is controlled by pulses of gonadotropin-releasing hormone (GnRH) from the hypothalamus. Those pulses, in turn, are subject to the estrogen feedback from the gonads. LH levels are normally low in men during childhood. During the reproductive years typical male LH levels are between 5-20 mIU/ml. Physiologic high LH levels are seen during the LH surge. They typically they last 48 hours.
Persistently high LH levels are indicative of situations where the normal restricting feedback from the gonad is absent, leading to a higher pituitary production of both LH and FSH. High levels of LH and FSH in men may indicate gonadal dysgenesis, Turner Syndrome, castration testicular failure or CAH. Congenital adrenal hyperplasia (CAH) refers to any of several autosomal recessive diseases resulting from mutations of genes for enzymes mediating the biochemical steps of production of cortisol from cholesterol by the adrenal glands (steroidogenesis). Most of these conditions involve excessive or deficient production of sex steroids. Diminished secretion of LH can result in failure of gonadal function (hypogonadism), which is a medical condition that is typically manifested in males as failure in production of normal numbers of sperm.
LH is available mixed with FSH in the form of Pergonal or Menopur), and other forms of gonadotropins . More purified forms of gonadotropins may reduce the LH portion in relation to FSH. Recombinant LH is available as lutropin alfa (Luveris). All these medications have to be given parenterally. They are commonly in infertility therapy to stimulate follicular development, notably in IVF therapy. HCG medication is often used as a substitute for LH because it activates the same receptor. HCG medication is derived from urine of pregnant women, less costly, and has a longer half-life than LH. (Source: Wikipedia).
Spermatogenesis is the process by which male spermatogonia develop into mature spermatozoa. Spermatozoa are the mature male gametes in many sexually reproducing organisms. Spermatogenesis produces mature male gametes, commonly called sperm but specifically known as spermatozoa, which are able to fertilize the counterpart female gamete, the oocyte, during conception to produce a single-celled individual known as a zygote. This is the cornerstone of sexual reproduction and involves the two gametes both contributing half the normal set of chromosomes (haploid) to result in a chromosomally normal (diploid) zygote.
Spermatogenesis takes place within several structures of the male reproductive system. The initial stages occur within the testes and progress to the epididymis where the developing gametes mature and are stored until ejaculation. The seminiferous tubules of the testes are the starting point for the process, where stem cells adjacent to the inner tubule wall divide in a centripetal direction-beginning at the walls and proceeding into the innermost part, or lumen-to produce immature sperm. Maturation occurs in the epididymis and involves the acquisition of a tail and hence motility.
Hormonal control of spermatogenesis varies among species. In humans the mechanism are not completely understood, however it is known that initiation of spermatogenesis occurs at puberty due to the interaction of the hypothalamus, pituitary gland and Leydig cells. If the pituitary gland is removed, spermatogenesis can still be initiated by follicle stimulating hormone and testosterone. (Source: Wikipedia).
Follicle stimulating hormone (FSH) stimulates both the production of androgen binding protein by Sertoli cells, and the formation of the blood-testis barrier. Androgen binding protein is essential to concentrating testosterone in levels high enough to initiate and maintain spermatogenesis, which can be 20-50 times higher than the concentration found in blood. Follicle stimulating hormone (FSH) may initiate the sequestering of testosterone in the testes, but once developed only testosterone is required to maintain spermatogenesis. However, increasing the levels of follicle stimulating hormone will increase the production of spermatozoa by preventing the apoptosis of type A spermatogonia. The hormone inhibin acts to decrease the levels of follicle stimulating hormone.
The Sertoli cells themselves mediate parts of spermatogenesis though hormone production. They are capable of producing the hormones estradiol and inhibin. The Leydig cells are also capable of producing estradiol in addition to their main product testosterone.
In this male infertility treatment follicle stimulating hormone (FSH) is administered to treat male infertility by increasing the both the production of androgen binding protein by Sertoli cells, and the formation of the blood-testis barrier. After the androgen binding protein initiates the sequestering of testosterone in the testes and thereby causes testosterone concentration in levels high enough to initiate and maintain spermatogenesis, the LH and HCG stimulate the testes to increase the production of testosterone to maintain spermatogenesis. And spermatogenesis is the process of creating sperm. This treatment requires that a patient present with a insufficient levels of naturally produced LH or FSH or deficient in both LH and FSH. The gonadotropins FSH and LH in combination with HCG induces spermatogenesis in hypogonadotropic men. (Source: Wikipedia).
This medical protocol does not include the administration of recombinant FSH to induce spermatogenesis. However, a medical treatment that includes the use of recombinant FSH may be indicated if the administration of the urinary FSH gonadotropin does not increase both the production of androgen binding protein by Sertoli cells, and the formation of the blood-testis barrier. The increase in testosterone production alone by LH or HCG is not sufficient to cause spermatogenesis in hypogonadotropic men. There must also be an FSH induced increase both the production of androgen binding protein by Sertoli cells, and the formation of the blood-testis barrier to increase the production of the androgen binding protein, which initiates the sequestering of testosterone in the testes and thereby causes testosterone concentration in levels high enough to initiate and maintain spermatogenesis. It is at this time that the increased production of testosterone resulting from the stimulation of the testes by administration of HCG and LH is essential to maintaining spermatogenesis
HCG is approved for use in cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency). It is used to stimulate the testes of men who are hypogonadal or lack sufficient testosterone production.
Diagnosis of Oligozoospermia
No single medical treatment has proven to be consistently reliable in increasing sperm count for patients diagnosed with Oligozoospermia or low sperm count. A diagnosis of Oligozoospermia is based on a symptom wherein a sample of semen contains less than 20 million spermozoa per ml of ejaculate.
Increasing Spermatogenesis in Hypogonadotropic Men
"Like urinary FSH, recombinant FSH in combination with HCG seems to induce spermatogenesis in hypogonadotropic men" See Drug Treatment of Male Fertility Disorders by Gerhard Haidl, et al. and specifically the discussion of HCG therapy therein. This article is located at URL: http://www.asiaandro.com/1008-682X/2/81.htm (Source: Wikipedia).
The Decline in Gonadal Stimulating Pituitary Hormone LH (Luteinizing hormone)
The natural decline in male testosterone production that occurs with aging is attributed to a decline in the gonadal stimulating pituitary hormone LH (Luteinizing hormone). As a result of the hypothalamus secreting less gonadoropin-releasing hormone (GhRH), which stimulates the pituitary gland to produce LH, the pituitary gland produces declining amounts of LH. This decrease in the pituitary secretion of LH reduces the stimulation of the gonads or male testes and results in declining testosterone and sperm production due to the decreased function of the gonads.
The decreased stimulation of the testes by the pituitary's diminished secretion of LH can also cause testicular atrophy. HCG stimulates the testis in the same manner as naturally produced. HCG Therapy is administered medically to increase male fertility by stimulating the testes to produce more sperm cells and thereby increase sperm count or Spermatogenesis.
How HCG Therapy Increases Plasma Testosterone Level in Hypogonadotropic Men
HCG therapy uses the body's own biochemical stimulating mechanisms to increase plasma testosterone level during HCG therapy. It is used to stimulate the testes of men who are hypogonadal or lack sufficient testosterone.
The male endocrine system is responsible for causing the testes to produce testosterone. The HPTA (hypothalamic-pituitary-testicular axis) regulates the level of testosterone in the bloodstream. and . The hypothalamus produces gonadotropin-releasing hormone (GnRH), which stimulates the pituitary gland to release Luteinizing hormone (LH).
LH released by the pituitary gland then travels from the pituitary via the blood stream to the testes where it triggers the production and release of testosterone. Without the continuing release of LH by the pituitary gland, the testes would shut down their production of testosterone, causing testicular atrophy and stopping natural testosterone produced by the testes.
As men age the volume of hypothalamus produced gonadotropin-releasing hormone (GnRH) declines and causes the pituitary gland to release less Luteinizing hormone (LH). The reduction if the volume of LH released by the Pituitary gland decreases the available LH in the blood stream to stimulate the testes to produce testosterone.
In males, HCG mimics LH and increases testosterone production in the testes. As such, HCG is administered to patients to increase endogenous (natural) testosterone production. The HCG medication administered combines with the patient's own naturally available LH released into the blood stream by the Pituitary gland and thereby increases the stimulation of the testes to produce more testosterone than that produced by the Pituitary released LH alone. The additional HCG added to the blood stream combined with the Pituitary gland's naturally produced LH triggers a greater volume of testosterone production by the testes, since HCG mimics LH and adds to the total stimulation of the testes.
In this treatment HCG is administered to men to promote an increase in sperm production (spermatogenesis) by the testes. HCG combined FSH or both LH and FSH is also used to increase male spermatogenesis and medically treat male infertility. (Source: Wikipedia)
Patient's May Incur Additional Medical Laboratory Diagnostic Testing Fees
In addition to our published fees for this treatment, the patient shall incur additional costs for sperm count or male fertility testing. The patient can secure requested male fertility diagnostic tests through their primary physician and such tests are covered by medical insurance coverage accepted by the patient's primary physician. The effective out-of-pocket costs for such testing can be reduced thereby.
A High Protein Diet Combined with Nutritional Supplements Consisting of Amino Acids, Vitamin C and Anti-oxidants is Recommended During the Treatment Period to Repair Sperm Cell DNA damage
During this medical treatment , it is requested that you follow a high protein diet combined with amino acids vitamin E, Vitamin C and anti-oxidants to reduce DNA damage in the sperm cells that are produced during the course of treatment.
Conditional Enrollment and Refund of Patient's Medical Retainer Fee Paid Clinic
A patient's enrollment in a medical treatment program is subject to the approval of the assigned National Medical Clinic, Inc treating physician. The approval of a treatment program and issuance of written prescriptions is based upon the patient's medical complaint, symptoms (subjective findings), medical laboratory diagnostic testing (objective findings), patient's physical examination results, patient's medical history, physician's clinical assessment-evaluation of the patient and there existing a nexus relationship between the medical condition to be treated and the mediation prescribed. If the treating physician declines to prescribe the patient's sought treatment, then National Medical Clinic, Inc. shall returns to the patient 100% of the retainer fee/purchase funds paid less the incurred fees for the physical examination and clinical assessment of the patient, laboratory diagnostic blood testing and clinic fees.
While there are no guarantees in the practice of medicine, we look forward optimistically to working with you to jointly achieve a successful result for both you and your spouse or female partner.
MALE MEDICAL FERTILITY TREATMENTS
PROVIDED PATIENTS BY NATIONAL MEDICAL CLINIC, INC. PHYSICIANS
Medical Treatments for Male Patients with Insufficient LH to Increase Testosterone Production by Testes:
Medical Treatments for Male Patients with Insufficient FSH Production to Increase Available FSH:
- Pharmacy Compounded or Pharmaceutically Manufactured HCG to Increase Testosterone Production
- Pharmaceutically Manufactured Urinary LH to Increase Testosterone Production
- HCG and Pharmaceutically Manufactured Urinary LH to Increase Testosterone Production
Medical Treatments for Male Patients with Insufficient LH and FSH Production to
- Pharmaceutically Manufactured Urinary FSH
- Pharmaceutically Manufactured Recombinant FSH (Gonal F, Follistim)
Increase Testosterone Production by Testes and Available FSH:
- Combined HCG and Pharmaceutically Manufactured Urinary FSH
- Combined Pharmaceutically Manufactured Urinary LH and FSH (Pergonal or Menopur)
- Combined HCG, Pharmaceutically Manufactured Urinary LH and FSH (Pergonal or Menopur)
- Combined Pharmaceutically Manufactured Urinary LH and Recombinant FSH (Gonal F, Follistim)
- HCG, Combined Pharmaceutically Manufactured Urinary LH and Recombinant FSH (Gonal F, Follistim)